PDS Biotechnology reported promising interim data of the PDS0101 and Pembrolizumab combo in HNSCC

CAR-T Digest - August 2020

May 25, 2023: PDS0101 (SC) / Pembrolizumab (IV) / Head and Neck Cancer / PDS Biotechnology: Encouraging data from Phase 2 VERSATILE-002 study

PDS Biotechnology reported encouraging data from Phase 2 VERSATILE-002 study investigating PDS0101 in combination with Pembrolizumab
Key safety and efficacy data from the VERSATILE-002 study
- Estimated 12-month overall survival rate was 87.1% with published results of 36-50% with approved ICIs
- Median progression-free survival was 10.4 months with published results of 2-3 months with approved ICIs
- Disease control rate of 70.6%
- Confirmed and unconfirmed ORR: 41.2% (14/34 pts)
- 8.3% of patients had a grade 3 treatment-related adverse event (TRAE)
- No grade 4 or higher TRAEs were observed
Detailed results will be featured in ASCO 2023